Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
This review will provide an overview of the principles of pharmacogenomics from basic discovery to implementation, encompassing application of tools of contemporary genome science to the field (including areas of apparent divergence from disease-based genomics), a summary of lessons learned from the extensively studied drugs clopidogrel and warfarin, the current status of implementing pharmacogenetic testing in practice, the role of genomics and related tools in the drug development process, and a summary of future opportunities and challenges.
['Roden|Dan M|DM|', 'Van Driest|Sara L|SL|', 'Wells|Quinn S|QS|', 'Mosley|Jonathan D|JD|', 'Denny|Joshua C|JC|', 'Peterson|Josh F|JF|']
D000076103:Biological Variation, Individual D001711:Biotransformation D002317:Cardiovascular Agents D000076722:Drug Development D064420:Drug-Related Side Effects and Adverse Reactions D005544:Forecasting D056726:Genetic Association Studies D020022:Genetic Predisposition to Disease D005820:Genetic Testing D014644:Genetic Variation D023281:Genomics D060005:Genotyping Techniques D016045:Human Genome Project D006801:Humans D010597:Pharmacogenetics D057285:Precision Medicine D016032:Randomized Controlled Trials as Topic D018570:Risk Assessment D018401:Sample Size
genomics clopidogrel warfarin pharmacogenetics pharmacokinetics